90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas
Titel:
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas
Auteur:
Bouabdallah, K. Furst, S. Asselineau, J. Chevalier, P. Tournilhac, O. Ceballos, P. Vigouroux, S. Tabrizi, R. Doussau, A. Bouabdallah, R. Mohty, M. Le Gouill, S. Blaise, D. Milpied, N.